Neb. Rev. Stat. §§ 71-9602

Current with changes through the 2024 First Special Legislative Session

Section 71-9602 - Terms, defined

For purposes of the Investigational Drug Use Act:

(1) Advanced illness means any progressive disease or medical or surgical condition that entails significant functional impairment, that is not considered by a treating physician to be reversible even with administration of federally approved and available treatments, and that, without life-sustaining procedures, would likely result in death within six months;

(2) Eligible patient means a person who meets the requirements of section 71-9603;

(3) Health care provider has the same meaning as in section 71-7907;

(4) Investigational drug, biological product, or device means any drug, biological product, or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration;

(5) Physician means any person who is licensed to practice medicine and surgery pursuant to the Medicine and Surgery Practice Act; and

(6) Written, informed consent means a writing which conforms to section 71-9604.

Neb. Rev. Stat. §§ 71-9602

Laws 2018, LB 117, § 2.

Added by Laws 2018, LB 117,§ 2, eff. 7/19/2018.